188 related articles for article (PubMed ID: 22661650)
21. Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization.
Yodoi Y; Tsujikawa A; Nakanishi H; Otani A; Tamura H; Ojima Y; Hayashi H; Yoshimura N
Am J Ophthalmol; 2009 May; 147(5):816-24, 824.e1. PubMed ID: 19211092
[TBL] [Abstract][Full Text] [Related]
22. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks.
Sawa M; Gomi F; Tsujikawa M; Sakaguchi H; Tano Y
Am J Ophthalmol; 2009 Oct; 148(4):584-590.e2. PubMed ID: 19541288
[TBL] [Abstract][Full Text] [Related]
23. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results.
Ruiz-Moreno JM; Gomez-Ulla F; Montero JA; Ares S; Lopez-Lopez F; Rodriguez M; Fernandez M
Eye (Lond); 2009 Feb; 23(2):334-8. PubMed ID: 18064056
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal bevacizumab for choroidal neovascularisation in serpiginous choroiditis.
Parodi MB; Iacono P; La Spina C; Knutsson KA; Mansour A; Arevalo JF; Bandello F
Br J Ophthalmol; 2014 Apr; 98(4):519-22. PubMed ID: 24414400
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
26. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
[TBL] [Abstract][Full Text] [Related]
27. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia.
Wakabayashi T; Ikuno Y; Gomi F
Retina; 2011 May; 31(5):880-6. PubMed ID: 21242860
[TBL] [Abstract][Full Text] [Related]
28. Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses.
Ruiz-Moreno JM; Montero JA; Amat-Peral P
Graefes Arch Clin Exp Ophthalmol; 2011 Apr; 249(4):595-9. PubMed ID: 21234588
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.
Zhang H; Liu ZL; Sun P; Gu F
Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109
[TBL] [Abstract][Full Text] [Related]
31. Intravitreal bevacizumab for myopic choroidal neovascularization: short-term and 1-year results.
Spielberg L; Leys A
Bull Soc Belge Ophtalmol; 2009; (312):17-27. PubMed ID: 19927486
[TBL] [Abstract][Full Text] [Related]
32. [Treatment of high myopic choroidal neovascularisation with intravitreal bevacizumab].
Mathieu B; Isaico R; Ramel JC; Bron AM; Creuzot-Garcher C
J Fr Ophtalmol; 2014 Jan; 37(1):54-7. PubMed ID: 24210931
[TBL] [Abstract][Full Text] [Related]
33. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study.
Chan WM; Lai TY; Liu DT; Lam DS
Br J Ophthalmol; 2009 Feb; 93(2):150-4. PubMed ID: 18801766
[TBL] [Abstract][Full Text] [Related]
34. Intravitreal ranibizumab for the treatment of pathological myopia associated with choroidal neovascularization in Chinese patients.
Yang X; Dai H
Chin Med J (Engl); 2014; 127(16):2906-10. PubMed ID: 25131225
[TBL] [Abstract][Full Text] [Related]
35. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia.
Hernández-Rojas ML; Quiroz-Mercado H; Dalma-Weiszhausz J; Fromow-Guerra J; Amaya-Espinosa A; Solís-Vivanco A; Reyna-Castelán E; Abraham-Marín M; Martínez-Castellanos MA; Aiello LP
Retina; 2007; 27(6):707-12. PubMed ID: 17621179
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal bevacizumab in inflammatory ocular neovascularization.
Mansour AM; Mackensen F; Arevalo JF; Ziemssen F; Mahendradas P; Mehio-Sibai A; Hrisomalos N; Lai TY; Dodwell D; Chan WM; Ness T; Banker AS; Pai SA; Berrocal MH; Tohme R; Heiligenhaus A; Bashshur ZF; Khairallah M; Salem KM; Hrisomalos FN; Wood MH; Heriot W; Adan A; Kumar A; Lim L; Hall A; Becker M
Am J Ophthalmol; 2008 Sep; 146(3):410-416. PubMed ID: 18619571
[TBL] [Abstract][Full Text] [Related]
37. Summary of prognostic factors for choroidal neovascularization due to pathological myopia treated by intravitreal bevacizumab injection.
Wang J; Kang Z
Graefes Arch Clin Exp Ophthalmol; 2012 Dec; 250(12):1717-23. PubMed ID: 23007232
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
[TBL] [Abstract][Full Text] [Related]
39. Intravitreal injection of 2.5 mg bevacizumab for treatment of myopic choroidal neovascularization in treatment-naive cases: a 2-year follow-up.
Chen CH; Wu PC; Chen YJ; Liu YC; Kuo HK
J Ocul Pharmacol Ther; 2011 Aug; 27(4):395-400. PubMed ID: 21770740
[TBL] [Abstract][Full Text] [Related]
40. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]